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Statement 1996 CA-SFM 
Zone sizes and MIC breakpoints 
for non-fastidious organisms 




S R S R content Antimicrobial agent 
Penicillin 5 0.25 > 16 t 29 < 8  




1 4  
1 4  
5 4  





t 19 < 14 
t 19 < 14 
t 21 < 14 
t 21 < 14 
10 Pg 
l o l l 0  pg  
25 Pg 
20110 pg 
Ti~arcillin'~~ (when testing Enterobacteriaceae 
Ticarcillin/clavulaiiic acidR 
and Pseudomonas aerugino.w) 
(when testing Enterobacteriaceae 
and I? aeruginosa) 
1 16 > 64 t 22 < 18 75 Pg 
1 16 > 64 t 22 < 18 75/10 pg  
Mezlocillin' 
Azlocillin (when testing I? aerqinosa) 
Pipera~illin'.~ (when testing Enterobacteriaceae) 
Piperacillin/tazobactam9 (when testing Enterobacteriaceae) 
Piperacillin/tazobactam9 (when testing r? aeniginosa) 
Oxacillin'" (when testing staphylococci) 
(when testing I! aeruginosa) 
1 8  
1 16 
1 8  
1 1 6  








t 21 < 16 
t 19 < 13 
t 20 < 12 
t 18 < 12 
2 21 < 14 







1 2  > 2  t 20 < 20 
Mecillinam" 1 2  2 22 < 18 
Imipenemz~"' 
Meropenem"' 
1 4  
1 4  
2 22 < 17 
t 20 < 15 
5 4  > 32 t 23 < 17 




1 4  
1 8  




t 22 < 15 
t 22 < 15 
t 22 < 15 
Cefoxitin"' 
Cefotetan"' 
1 8  
1 4  
> 32 
> 32 
t 22 < 15 
t 23 < 17 
2 4  
1 4  




2 21 < 15 
t 21 < 15 
2 21 < 15 
(Continued) 
S46 
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Antimicrobial agent S R S R content 
Cefoperazone"' 
Ceftazidime"J.12 
Cefsulodin (when testing J? aeruginosa) 
Cefepiine2~"'~" 
Cefpirome2~"J~'2 


































1 4  
1 4  
1 8  
5 4  
1 4  
5 4  
1 8  
1 8  
1 8  
1 2  
1 2  
1 2  
1 1  
1 1  
1 1  
1 1  
1 250 
1 8  
1 250 
1 8  
s 4  
1 4  
s8 
1 8  
5 250 
5 4  
1 4  
1 4  
1 64 
1 8  
1 4  
1 4  
1 4  
1 1  
s 0.12 
1 0.12 
1 1  
t 21 < 14 
t 21 < 15 
t 22 < 14 
t 21 < 15 
t 21 < 15 
t 23 < 17 
t 18 < 12 
t 18 < 12 
2 18 4 12 
t 22 < 16 
t 22 < 15 
t 23 < 14 
t 22 < 19 
t 26 < 20 
2 25 < 22 
2 24 < 21 
2 14 < 12 
t 15 < 13 
t 14 < 10 
t 17 < 15 
2 16 < 14 
t 16 < 14 
t 17 < 15 
t 17 < 15 
2 17 < 11 
t 16 < 14 
t 16 < 14 
t 19 < 17 
t 23 < 19 
t 19 < 17 
t 19 < 17 
2 19 < 17 
t 22 < 17 
2 28 < 16 
2 32 < 19 


















S R content 
t 21 < 17 15 IQ 
t 15 < 15 2 UI 
Antimicrobial agent S R 
Clindamycin 1 2  > 2  
Lincomycin 1 2  > 8  
Pristmamycin 
Virginiamycin 
1 2  > 2  
1 2  > 2  
Bacitracine 1 2  > 2  
colistinl8 1 2  > 2  2 15 < 15 50 wg 
Sulfonamides I ’ 
Trimethopriml’ 
Trimethoprim-sulfamethoxazolezo 
1 1 0 0  > 350 
1 4  > 8  
1 2 / 3 8  >8/152 
200 kg 
t 16 < 12 5 kg 
t 17 < 12 
< 10 2 16 
2 17 < 14 
1.25 + 23.75 pg 
300 Pg Furanes” 1 25 7 100 
Oxolinic 




1 2  > 4  
1 4  > 8  
1 8  > 16 
S8 > 16 
1 16 > 32 
Rosoxacin (when testing N. gonorrhotoe) 1 1  > 1  
6 1  > 2  
1 1  > 2  
1 1  > 2  
2 22 < 19 5 
2 22 < 19 5 Pg 





1 1  > 4  
1 1  > 4  
1 1  > 2  
1 1  > 2  




1 3 2  > 32 
1 2  > 16 
6 4  > 4  
Teic~planin~~ 
Vancomy tin'“ 
1 4  > 16 
5 4  > 16 
t 17 
t 17 
Nitroxolin” 1 1  > 32 
S = susceptible, R = resistant 
Notes 
1. Result applies to group G penicillins. 
2. Use a 5 pg-oxacillin disk to detect resistance to penicillin G in pneumococci; susceptible strain, zone diameter t 26 mm. 
There is cross-resistance between penicillin G and other p-lactams in pneumococci. 
For strains with a zone diameter < 26 mm, MICs of penicillin G and of the following p-lactams should be determined amoxicillin, 
imipenem, cefuroxime, cefotaxime, ceftriaxone, cefepime, cefpirome. MIC breakpoints of these antibiotics (parenteral use) for 
pneumococci are as follows: 
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LLR: low level of resistance HLR: high level of resistance 
S I (LLR) R (HLR) 
Penicillin G 5 0.06 0.12-1 > 1  
Other p-lactams (above-mentioned) 5 0.5 1-2 > 2  
3.  Result applies to bacampicillin, metampicillin and pivampicillin. 
4. Klebsiella spp. are naturally producers of a p-lactamase at a low level. Amino-, carboxy- and ureidopenicillins are inactivated by this 
5. MIC breakpoints expressed in ampicillin, u i n g  tulbactam at 8 Fg/mL. 
6. MIC breakpoints expressed in amoxicillin, using clavulanic acid at 2 pg/mL. 
7. Applicable for intravenous administration. 
8. MIC breakpoints expressed in ticarcillin, using clavulanic acid at 2 Fg/mL. 
9. MIC breakpoints expressed in piperacillin, using tazobactam at 4 pg/mL. 
enzyme. If these strains appear susceptible, they should be considered as ‘intermediate’ to these products. 
10. Results apply to all p-lactams, testing a t  30°C or on Mueller-Hinton agar plus 5% NaCl at 37 O C .  Weak growth can be observed after a 
24-h incubation, especially with coagulase-negative staphylococci. In this case, use a lo7 UFC/mL inoculum or a 48-h incubation 
1 1. Result applies to parented first-generation cephalosporins. 
12. Enterobacteriaceae, especially Klebsiella pneumoniae, producers of extended-spectrum p-lactaniases, may appear susceptible to third- 
generation cephalosporins and aztreonam. In case of a positive synergy test between these products and a P-lactamase inhibitor such as 














around a disk of amoxicillin + clavulanate 30 mm apart (center to center). 
Result applies to neomycin, franiycetin and paromomycin. 
Streptococci and enterococci are resistant to aminoglycosides at a low level (LLR). Use only high-charged disks of streptomycin (S), 
kanamycin (K) and gentamicin (G) to detect a high level of resirtance (HLR) to aminoglycosides. 
SUNR, KBNR and GBNR: possible synergistic effect in combination with p-lactanis. 
No synergistic effect is observed: 
sHNK for streptomycin. 
KHNK for kanamycin, amikacin and isepamicin. 
G”NR for kanamycin, tobramycin, dibekacin, amikacin, isepaniicin, gentamicin, sisomicin and netilmicin. 
In the case of intermediate strains, the level of resistance should be confirmed by agar or broth dilution in the presence of 
1000 pg/mL of S, K or G. 
Result applies to thiamphenicol. 
Result applies to roxithromycin and clarithromycin. 
Result applies to josamycin and midecamycin. 
Result applies to polymyxins. 
Result applies only to organisms isolated from urinary tract infections. 
Result applies to all combinations trimethoprim-sulfonamides. 
Result obtained with one compound applies to all first-generation quinolones. 
There is cross-resistance to fluoroquinolones uqed in urinary tract infections, but the level of expression may vary depending on the 
bacterium. 
There is cross-resistance to fluoroquinolones (FQ) used in systemic infections but the level of expression may vary depending on the 
bacterium: 
Staphylococci: results obtained with one drug apply to others. 
Streptococci (except S. ptieumoniae) and enterococci: F Q  are not advised. 
S. pneumoniae: sparfloxacin, ofloxacin and ciprofloxacin can be used in pneumococcal infections, according to their therapeutic 
indications. Therefore, these compounds should be tested on this species. 
Enterobacteriaceae and Pseudomonar aeruginosa: every compound should be tested separately. 
For zone diameters < 17 mm, MICs should be determined. 
MIC breakpoints apply to organisms isolated from uncomplicated urinary tract infections. 
